Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
First of all the correct term as announced is an acquisition by IMUN of Aletheia Therapeutics Corp. in an all-stock transaction. If indeed that has been accomplished then not just an announcement of such completion but an SEC 8-K filing would certainly be required as the acquisition would be a material event. Secondly, if indeed the acquisition has been completed as shareholders we need to know what the exact parameters are regarding the stock quantity involved and what IMUN is exactly acquiring.
Where in either of the two press releases of February 11 or 18, 2020, respectively, did it indicate that "they completed the merger"?? Where??
I just hope some other poster(s) can explain the previous response!
Still not providing explanation as to how you make the conclusion that Handley will be the majority shareholder. Do you know what the purported merger arrangements are? Shares to be exchanged for ownership of Aletheia Therapeutics Corp., etc. ??
Yes, Now you are promulgating the correct question!
Majority shareholder of which company- IMUN? Please explain!
Would be interested in kowing what is said on the Facebook posting regarding the Aletheia merger (IMUN acquisition of Aletheia in all-stock transaction), if anything? Any indication perhaps as to what assets IMUN will be obtaining in such stock purchase? Thank you.
Oh really? First-what patents are transferable?? And second-how do you know such patents are transferable and can be assigned to IMUN??
I have seen your link to the patent list for Mr. Handley containig 13 patent applications (pending) and 9 issued patents wherein he is listed along with several other individuals on each as one of the inventors. However, on the 9 issued patent he is not listed as an assignee nor is Aletheia Therapeutics Corp. Obviously, perhaps, he has arranged a license agreement to one or more of these 9 issued patents for Aletheia. If so, then these are protected IP products and no reason not to indicate them or others in Aletheia's purported "diverse oncology product pipeline". Since a reported IMUN stock purchase is to be closed " early in the first quarter of 2020 " what is in the pipeline??
Mr. Handley indicated in the December 16, 2019 PR Wire release "...Aletheia's diverse oncology product pipeline...." Does anyone have any information as to what are the "products" in this pipeline?? Any information, i.e. chemical names, etc.?? Since it was announced that IMUN will acquire Aletheia in an all-stock transaction it seems as IMUN shareholders it would be more than appropriate to know what these "products" are, etc., as they would be the major/only assets of the transaction.
What does " Aletheia's immune-oncology pipeline" include?? Anyone know??
I believe that the most important information in the IMUN Press Release dated December 16, 2019 is the following:
" Furthermore, Aletheia has signed definitive stock purchase agreement with an investor group for $ 25 million that should fund before the end of the year."
Wonder if such has occurred??
If that is your source of information than as of April 19, 2019 the total invested in that Company is indicated as $ 165,012.00--obviously long way to go to get to $ 20,000,000.00.
How do you know that Company already has the investors?? Based on what form of information is your claim made??
You are misrepresenting/misinforming others in a public forum. You clearly stated to me in post #11162 that "You are missing the big picture Imun - has acquired exclusive rights to naltrexone". That definitively infers that IMUN has exclisuive rights to all regarding naltrexone. That is not a correct statement and is misleading! In response to my request you send a link dated back to 2013 wherein an announcement was issed by IMUN regarding the exclusive licensing rights garnered by IMUN to Penn State Universitry and separate Jill Smith, M.D, patents for the use of Low Dose Naltrexone (LDN) in the treatment of specific disease entities-period-that is all the exclusivity.
Exclusive rights to naltrexone??? When, How??? Please inform us regrading the specific documentation of this exclusivity by direct links or reference to SEC filings or public announcements!
Let me instruct you and others looking at your list of Naltrexone studies--The ONLY clinical studies potentially relevant to IMUN are those using Low Dose Naltrexone (LDN). No Others have any relevance to the purported utility of this chemical as proposed by IMUN. Reduce your list accordingly and then resubmit the public posting.
Thank you for the input about speaking to the newly hired CEO of IMUN. I know others as well as myself would be most interested and appreciative if you could expand for us from this discussion you had with him that led you to the assessment of him as Sharp.
American Hospitals is a name of an entity founded and owned in Lagos, Nigeria by Dr. Richards Afonja and is primarily a clinic for the treatment of cancer patients. This is the same Richards Afonja that is the founder of AHAR Pharmaceuticals. Sound familiar?? Your inference here is that there is ubiquitous use of Lodonal in many hospitals in Nigeria. Unless presented with accurate and verifiable information to the contrary, I do not believe such is true at all!
What market in Africa-very large continent. BE Specific. What country(ies)?
What product in which market??
OK-thank you for checking once you are able. Would be most important to know in which country LDN has approval for marketing to treat cancer. If such is in the 10-K that information will certainly require some investigation.
Where is LDN approved for marketing for the treatment of cancer??
You completely missed the point--You referred to him as Dr.(as in Doctor) Mike H. He does not hold a Doctorate in any area-period! Just plain ole' Mike H. if that is what you want to call him.
Get the facts straight--Michael K. Handley is NOT a Dr. Mike H.-not even close!
What product to be marketed??
Interesting to note your very firm knowledge of Griffin resignation(s) even though yesterday's release was not at all clear about the dual resignations. Also, according to your firm knowledge of the situation she has "left the company completely" is not accurate as you state she will be the CEO of Cytocom which is still partly owned by IMUN.
It is not completely clear to me from the wording in the announcement released today that Griffin is also resigning as a member of IMUN's Board of Directors as well as resigning as CEO. Appreciate input fron others on their thoughts.
Be very, very careful in your public statements! Neither Immune Therapeutics, Inc., nor Cytocom, Inc., have initiated any FDA approved clinical studies in the Crohn's Disease area to prompt your statement: "The Company has reported very good results and the chance for approval is very high."
Thank you for the reply and link in response to my questioning the term "proven" that you have used. I am very familiar with the link site that you provided and others that are similar. IMUN is and was established as a company to bring to market a therapeutic entity. In order to do so, whether here or elsewhere in the world, drug therapeutic agents must be proven by rigorous and well designed clinical studies to prove their safety and efficacy under the direct aegis of the appropriate drug regulatory agencies prior to approval to market. That then brings in revenue. This has not been done for either naltrexone or methionine enkephalin. Until then, anecdotal studies, no matter how many suggest the potential of the drug entity, but prove nothing that would lead to commercialization and revenue. Hence the current stock price of IMUN.
I am curious as to your assumptions in your post that the ..."drug is proven (in actuality there are two drug entities involved with IMUN). Although each entity no doubt has potential, what is/are your criteria(s) for proven, and for what utility, whether human or animal?
The most complete and accurate summary of the situation ever posted re: IMUN. Thank you!!
Spelling correction(and not surprising)! I believe Mylan is spelled Bristol-Myers Squibb.
Excellent!!
Food for thought--I believe the there is a direct correlation with the proposed reverse split of the common stock, proposed issuance of preferred shares, proposed name change and the YET unannounced issuance of the the U.S. Patent # 10,111,870. As stated previously, this patent is quite broad in covering potential therapy for LDN and, if claims hold up, very,very significant potential.
The link to the patent is above as a sticker post courtesy of dwarren. It bears noting!!
The only patent assigned to Cytocom, Inc. is the Jill Smith, M.D. and her group patent for the treatment of Crohn's Disease. As I stated in my posting on 11/07/18 the newly issued patent to Immune Therapeutics, Inc. is very broad and general in its coverage AND is potentially highly significant. I am still puzzled that all the shareholders out there do not seem to be responding to the implications-this is a new U.S. Patent covering the USE of LDN over a broad swath of therapeutic potential and IF the claims hold IMUN has the absolute rights to the commerce of these broad therapeutic potentials noted in the patent for at least 17 years.
NOW the question posed earlier--Where is the 8-K for this issued patent??
JA9791-Do you have any explanation as to how connecting directly through the same link to the Immune Therapeutics, Inc issued Patent No. 10,111,870 that you provided on 11/07/18 in your posting # 8500 now connects to a Patent no. 10,124,010 issued to MindImmune Therapeutics, Inc.???
I find it really interesting and puzzling that with one or two postings as exceptions, more curiosity and, even more importantly, a call out to all to really absorb the potential significance of the October 30, 2018 issued LDN patent. I wonder if any others have very carefully reviewed this very broad and new IP that lists IMUN as the applicant.
IMO, it is quite noticeable that to date we see no mention in the 10-Q as an "additional activity" after the September 30, 2018 closing date of the 10-Q and as of two weeks from issuance not one peep in the form of an 8-K.
The recent U.S. Patent was issued October 30, 2018. I would assume this would be a material event and require an 8-K filing. Well over a week and no indication of such filing and obviously no other announcement.
Would be most interested as a Cytocom, Inc. Shareholder to know specifically where you obtained the Cytocom, Inc. Shares Outstanding and the "prevailing" price/share?? Thank you!